[The therapeutic value of "Essential" phospholipids]

Area of Science:

• Biochemistry
• Pharmacology
• Cardiovascular Medicine

Background:

• Hyperlipidemia, characterized by elevated serum lipid levels, is a significant risk factor for cardiovascular diseases.
• Current therapeutic strategies for hyperlipidemia often involve lifestyle modifications and pharmacotherapy.

Purpose of the Study:

• To evaluate the efficacy of "Essential" phospholipids (Lipostabil, Lipostabil forte) as a treatment for various types of hyperlipidemia.
• To assess the impact of these phospholipids on serum lipid profiles, lipoprotein electrophoresis, coagulation, vascular health, blood pressure, and glucose tolerance.

Main Methods:

• A randomized controlled trial involving 73 patients (43 male, 30 female) with diverse hyperlipemia types.
• Patients received Lipostabil, Lipostabil forte, or placebo for one-month treatment periods.
• Comprehensive analysis included serum lipid levels, lipoprotein electrophoresis, coagulation parameters, assessment of coronary and peripheral vascular diseases, blood pressure, and glucose tolerance.

Main Results:

• Lipostabil demonstrated a statistically significant reduction in serum triglyceride levels specifically in patients with Type IV hyperlipemia.
• No significant effects were observed across all measured parameters for all hyperlipidemia types when using "Essential" phospholipids alone.
• The study indicated potential benefits in supporting existing hyperlipidemia treatments.

Conclusions:

• "Essential" phospholipids may not be sufficient as a standalone therapy for managing hyperlipidemia.
• These compounds could potentially play a supportive role in a comprehensive treatment regimen for hyperlipidemia, particularly for Type IV.
• Further research is warranted to elucidate the precise mechanisms and optimal application of phospholipids in hyperlipidemia management.